This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Minocycline hydrochloride

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221101

Version

5

Spl Product Data Elements

Minocycline hydrochloride Minocycline hydrochloride MINOCYCLINE HYDROCHLORIDE MINOCYCLINE STARCH, CORN MAGNESIUM STEARATE GELATIN TITANIUM DIOXIDE D&C RED NO. 33 FD&C RED NO. 3 FD&C YELLOW NO. 6 FERROSOFERRIC OXIDE PROPYLENE GLYCOL D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C BLUE NO. 2 FD&C RED NO. 40 SHELLAC AMMONIA ALUMINUM OXIDE pink body and cap CAPSULE 316 Minocycline hydrochloride Minocycline hydrochloride MINOCYCLINE HYDROCHLORIDE MINOCYCLINE ALUMINUM OXIDE D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C BLUE NO. 2 FD&C RED NO. 40 FERROSOFERRIC OXIDE GELATIN MAGNESIUM STEARATE PROPYLENE GLYCOL SHELLAC STARCH, CORN TITANIUM DIOXIDE light gray opaque body and white opaque cap CAPSULE 317 Minocycline hydrochloride Minocycline hydrochloride MINOCYCLINE HYDROCHLORIDE MINOCYCLINE ALUMINUM OXIDE AMMONIA D&C RED NO. 28 D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C BLUE NO. 2 FD&C RED NO. 40 FERRIC OXIDE RED FERROSOFERRIC OXIDE GELATIN MAGNESIUM STEARATE PROPYLENE GLYCOL SHELLAC STARCH, CORN TITANIUM DIOXIDE pink body and maroon cap CAPSULE 318

Application Number

ANDA063009

Brand Name

Minocycline hydrochloride

Generic Name

Minocycline hydrochloride

Product Ndc

70771-1427

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1426-1 Minocycline Hydrochloride Capsules USP, 50 mg 100 Capsules Rx only NDC 70771-1427-1 Minocycline Hydrochloride Capsules USP, 75 mg 100 Capsules Rx only NDC 70771-1428-7 Minocycline Hydrochloride Capsules USP, 100 mg 50 Capsules Rx only mino 50mg SEZ Minocycline Capsules, 75 mg mino 100mg SEZ

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.